Skip to main content
. 2016 Dec 2;31(4):551–559. doi: 10.1038/eye.2016.269

Figure 2.

Figure 2

Mean number (SD) of all ophthalmology visits in the first 12 months after treatment initiation for patients with (a) CRVO or (b) BRVO treated with ranibizumab injection or dexamethasone implant. Differences between treatment groups were compared after adjusting for baseline characteristics (age, sex, Charlson–Deyo Comorbidity Index, health plan type, and US geographical region). BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion; SD, standard deviation.